The fourth wave of the overdose crisis — driven by illicitly manufactured fentanyl, fentanyl analogs, and the veterinary sedative xylazine — has reshaped opioid use disorder care.
Alcohol use disorder remains the most prevalent substance use disorder yet the most undertreated, with fewer than ten percent of patients receiving evidence-based pharmacotherapy.
Stimulant use disorder has surged alongside the opioid crisis, with methamphetamine and cocaine now frequently co-detected with fentanyl in overdose decedents.
Behavioral addictions occupy a contested but expanding diagnostic space, with gambling disorder formally classified in DSM-5-TR and ICD-11, internet gaming disorder under continued study, and compulsive sexual behavior disorder added to ICD-11.
Harm reduction has moved from the margins to the center of US addiction policy following the 2022 federal endorsement of syringe services and OTC naloxone (Narcan, RiVive) approval.
Medications for addiction treatment remain dramatically underutilized despite decades of evidence, with fewer than a quarter of patients with OUD receiving buprenorphine, methadone, or naltrexone.
Recovery-oriented systems of care extend beyond acute treatment into the long-term supports that sustain remission.
Primary and secondary prevention strategies have shifted toward evidence-based, developmentally targeted interventions following decades of disappointing results from didactic programs like DARE.
The neurobiology of addiction has moved beyond the mesolimbic dopamine model into a circuit-level understanding spanning the ventral and dorsal striatum, prefrontal cortex, insula, and habenula.
Trauma and PTSD frequently underlie substance use disorders, and untreated trauma is one of the strongest predictors of relapse.
Adolescent substance use carries unique developmental risks and demands age-appropriate care models.
Maternal substance use sits at the intersection of obstetrics, neonatology, addiction medicine and child welfare.
Dual-diagnosis care integrates addiction treatment with management of depression, anxiety, bipolar disorder, psychosis and personality disorders.
Tobacco remains the deadliest substance use disorder globally with around eight million annual deaths.
Legalisation, high-THC products and the cannabis hyperemesis epidemic have reshaped cannabis-related clinical care.
Psilocybin, MDMA and ketamine sit at the contested frontier of addiction therapy.
Smartphone-based recovery, AI relapse prediction and remote contingency management have moved from research pilots to reimbursable clinical tools.
Drug policy frameworks decisively shape clinical outcomes and population mortality.
Office-based and OTP-delivered MOUD remains the backbone of opioid use disorder treatment in the US and globally.
Naloxone distribution and overdose-prevention strategies have evolved with OTC nasal naloxone approval, persistent fentanyl supply and rising xylazine adulteration.
Recovery housing supports the recovery process beyond formal treatment and addresses housing instability as a fundamental social determinant.
Lived-experience peer recovery workers have become a recognised, credentialed workforce within addiction treatment.
Addiction medicine training has expanded with ACGME fellowships, X-waiver elimination and the inclusion of addiction in core medical education.
Stigma remains a major barrier to addiction care, affecting treatment-seeking, clinician attitudes and policy.
Drug policy frameworks decisively shape clinical outcomes and population mortality.
Global drug trends shape national responses and inform evidence-based policy.
Substance use in older adults is under-recognised, rapidly growing, and intersects with polypharmacy and frailty.
Veterans face elevated rates of substance use disorders driven by combat exposure, military culture and post-discharge transition challenges.
Criminal-justice intersection with addiction treatment shapes outcomes for millions in the US and globally.
Family-based therapy is among the most effective treatment modalities for adolescent SUD and an important adjunct for adult recovery.
Spiritual and meaning-making frameworks shape many recovery pathways and remain controversial in evidence-based discussion.
Genetic and epigenetic mechanisms underlie addiction risk and treatment response with growing clinical relevance.
Most US overdoses now involve multiple substances, fundamentally changing the clinical picture.
The drug supply evolves rapidly, with new substances emerging faster than testing and treatment can adapt.
The addiction-treatment workforce needs urgent expansion to meet projected demand, with persistent recruitment and retention challenges.